Author:
Nathanson David,Sabale Ugne,Eriksson Jan W.,Nyström Thomas,Norhammar Anna,Olsson Urban,Bodegård Johan
Funder
AstraZeneca Nordic-Baltic
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy,Pharmacology
Reference34 articles.
1. International Diabetes Federation. IDF diabetes atlas. 2014.
http://www.diabetesatlas.org/
. Accessed 15 May 2017.
2. WHO. Global report of diabetes. Geneva: WHO; 2016.
http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf
. Accessed 15 May 2017.
3. Norhammar A, Bodegard J, Nystrom T, Thuresson M, Eriksson JW, Nathanson D. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013. Diabetologia. 2016;59(8):1692–701.
https://doi.org/10.1007/s00125-016-3971-y
.
4. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care. 2004;27(1):201–7.
5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clin Res Ed). 2000;321(7258):405–12.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献